Abrocitinib and Fluconazole interaction

Abrocitinib and Fluconazole: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Fluconazole label · effective 2026-04-02

Major

(See CLINICAL PHARMACOLOGY . ) Avoid concomitant use of abrocitinib with fluconazole.

Drug interactionsnames AbrocitinibView label on DailyMed
Moderate

Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed and are described in greater detail below: Abrocitinib Drug interaction studies indicate that when coadministered with fluconazole (strong inhibitor of CYP2C19; moderate inhibitor of CYP2C9 and CYP3A4), the systemic exposure of abrocitinib…

Drug interactionsnames AbrocitinibView label on DailyMed
Minor

Refer to the abrocitinib Prescribing Information for additional details.

Drug interactionsnames AbrocitinibView label on DailyMed

From the Abrocitinib (Cibinqo) label · effective 2026-09-09

Moderate

• Strong Inhibitors of CYP2C19 : The recommended dosage is 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily.

Drug interactionsby drug classView label on DailyMed
Moderate

Clinically Significant Drug Interactions Affecting CIBINQO Strong CYP2C19 Inhibitors Clinical Impact Concomitant use of CIBINQO with strong CYP2C19 inhibitors increases the combined exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO [see Clinical Pharmacology (12.3) ].

Drug interactionsby drug classView label on DailyMed
Moderate

Intervention Dosage reduction of CIBINQO is recommended when concomitantly used with strong CYP2C19 inhibitors [see Dosage and Administration (2.5) ].

Drug interactionsby drug classView label on DailyMed
Minor

Certain CYP2C19 Substrates Clinical Impact CIBINQO is a moderate inhibitor of CYP2C19.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.